ConductScience.org, home

Comparison · NCT05780437-sae

AZD7442 Plus SOC vs Placebo Plus SOC: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. AZD7442 Plus SOC vs Placebo Plus SOC: serious adverse events. Trial comparisons, record NCT05780437-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05780437-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.05070.03680.0694wilson
Risk in group 20.05520.04060.0745wilson
Risk difference, group 1 minus group 2-0.00446-0.02830.0192newcombe hybrid score
Risk ratio, group 1 over group 20.9190.5911.43log
Odds ratio, group 1 over group 20.9150.5741.46log
Number needed to treat, for one fewer participant with a serious adverse event on AZD7442 Plus SOC than on Placebo Plus SOC224from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AZD7442 Plus SOC
* AZD7442 600 mg solution (separate vials containing 300 mg each of AZD88995 and AZD1061); administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion~AZD7442: AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.~Remdesivir: Antiviral agent
36710EG000
Group 2Placebo Plus SOC
* Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion~Placebo: Commercially available 0.9% sodium chloride solution~Remdesivir: Antiviral agent
39707EG001

Harm

What it counts
Total, serious adverse events
Time frame
90 Days

Source ClinicalTrials.gov

Trial

Title
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT number
NCT05780437
Phases
PHASE3
Conditions
COVID-19
Interventions
AZD7442, Placebo, Remdesivir
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Results first posted
2024-07-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05780437-sae